A novel ERK-pathway inhibitor (PD098059) arrests invasion and growth of HNSCC in a murine model
Details
Serval ID
serval:BIB_96DEE4873D0D
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
A novel ERK-pathway inhibitor (PD098059) arrests invasion and growth of HNSCC in a murine model
Title of the conference
International Symposium on Metastases in Head and Neck Cancer
Address
Kiel, Germany, January 15-18, 1998
ISBN
1532-1827
ISSN-L
0007-0920
Publication state
Published
Issued date
1998
Volume
77
Series
British Journal of Cancer
Pages
47
Language
english
Notes
Meeting Abstract
Abstract
The prognosis for patients with HNSCC is intimately linked to
invasion of adjacent tissues. Thus, inhibition of protease expression
in HNSCC via interference with signal transduction pathways may
reduce invasive properties and improve survival. Recently, we have
shown that a specific ERK-pathway inhibitor ( PD 098059 ) arrests
invasion of UM-SCC1 cells in-vitro. We therefore investigated the
effect of PD 098059 on this cell line in-vivo. Using a quantitative
orthotopic murine model, stepwise invasion of the floor-of-mouth
and tongue were evaluated after subcutaneous tumour cell
injection. Intralesional administration of PD 098059 using
liposomes as a carrier was performed over a 25 day period (every
5 days with 15mM final concentration). Tumor growth arrest and
attenuation of tumor invasion occurred in 3 of 4 treated mice;
while tumor advanced into the genioglossus muscle in 4 of 5
control mice.
Therefore the inhibition of the ERK-signal transduction pathway
may become a powerful therapeutic adjuvant in combating invasion
ofHNSCC.
invasion of adjacent tissues. Thus, inhibition of protease expression
in HNSCC via interference with signal transduction pathways may
reduce invasive properties and improve survival. Recently, we have
shown that a specific ERK-pathway inhibitor ( PD 098059 ) arrests
invasion of UM-SCC1 cells in-vitro. We therefore investigated the
effect of PD 098059 on this cell line in-vivo. Using a quantitative
orthotopic murine model, stepwise invasion of the floor-of-mouth
and tongue were evaluated after subcutaneous tumour cell
injection. Intralesional administration of PD 098059 using
liposomes as a carrier was performed over a 25 day period (every
5 days with 15mM final concentration). Tumor growth arrest and
attenuation of tumor invasion occurred in 3 of 4 treated mice;
while tumor advanced into the genioglossus muscle in 4 of 5
control mice.
Therefore the inhibition of the ERK-signal transduction pathway
may become a powerful therapeutic adjuvant in combating invasion
ofHNSCC.
Web of science
Create date
22/01/2013 11:55
Last modification date
20/08/2019 14:58
Usage data
